Splenic irradiation within the last 6 months
History of prior or current splenectomy or splenic irradiation
Splenic irradiation within 12 months prior to screening, or prior splenectomy.
History of or current immunodeficiency disease, splenectomy or splenic irradiation
Splenic irradiation within 3 months prior to the first dose of study drug
History of or plan for splenectomy or splenic irradiation
Splenic irradiation within 3 months prior to Randomization
Splenic irradiation 3 months prior to enrollment.
At least 6 months from prior splenic irradiation
History of or current immunodeficiency disease (e.g. splenectomy or splenic irradiation)
Splenic irradiation within 3 months prior to the first dose of MMB
Phase 2 Part: Patients who have had prior splenectomy or have had splenic irradiation within 3 months of starting study drug
Splenectomy
History of splenectomy or planning to undergo splenectomy
Splenectomy
Prior splenectomy
Patients with history of splenectomy
Patients who have undergone splenectomy
Splenectomy ? 90 days prior to the first dose of PRTX-100
Patients having previously undergone splenectomy.
Previous history of splenectomy or whole spleen radiation
History of splenectomy
Prior splenectomy
Prior splenectomy
Subjects with splenectomy.
History of splenectomy
Prior splenectomy
Prior splenectomy
Patients having previously undergone splenectomy.
Prior splenectomy
Patients having undergone splenectomy.
Patients who have undergone splenectomy
Splenectomy (Phase 2 portion of the study only)
Patients with a prior history of a splenectomy and/or sickle cell trait/disease
Prior splenectomy unless Howell-Jolly bodies are absent.
History of splenectomy
Prior splenectomy
Patient is immunocompromised (patients with splenectomy are allowed).
Immunocompromised patient (Note: patients with splenectomy are allowed)
Immunocompromised patient (Note: patients with splenectomy are allowed)
Previous splenectomy
Immunodeficiency or splenectomy
Prior splenectomy
Previous hysterectomy and/or prior treatment for cervical precancer condition
Patients post hysterectomy and free from residual disease
Has undergone a previous hysterectomy defined as removal of the entire uterus or will have a hysterectomy as part of their initial cervical cancer therapy. NOTE: Women who have had a partial/subtotal hysterectomy are eligible to participate in the study
Participants must have undergone simple, modified radical, or radical abdominal hysterectomy or vaginal hysterectomy and lymphadenectomy (pelvic nodes, para-aortic nodes, or both nodal basins) by open or laparoscopic assisted technique
Evidence of measurable (macroscopic) residual disease following hysterectomy and lymphadenectomy
Prior hysterectomy
Patients must have undergone a hysterectomy (total abdominal hysterectomy, vaginal hysterectomy or radical hysterectomy, or total laparoscopic hysterectomy) for carcinoma of the cervix or endometrium within 49 days prior to registration; performance of a bilateral salpingo-oophorectomy will be at the treating surgeon’s discretion
Patients who have undergone a previous hysterectomy or will have a hysterectomy as part of their initial cervical cancer therapy; this includes patients with a prior history of supracervical hysterectomy
Patients who have had a simple hysterectomy (cut through hysterectomy)
Women who have undergone simple or radical hysterectomy prior to radiotherapy
Prior hysterectomy
Documented oophorectomy or hysterectomy
Participants who have undergone hysterectomy
Is not a candidate for immediate hysterectomy, following evaluation by a physician, due to desire to preserve fertility, due to degree of obesity, due to comorbidities, or due to patient refusal of hysterectomy
At least 2 months was passed since the hysterectomy at time of visit 2
Without hysterectomy
Women who self-report having received a hysterectomy
PRELIMINARY TEST: No history of hysterectomy
Report having had a hysterectomy
Have had hysterectomy
Prior hysterectomy
Prior hysterectomy with removal of the cervix
Women who have undergone a hysterectomy with removal of the cervix
Prior hysterectomy or endometrial ablation
Patients having undergone prior hysterectomy will be eligible provided that they meet the other requirements for entry into this study
obtaining surgical history (e.g., tubal ligation or hysterectomy)
Subjects with prior complete or partial hysterectomy involving removal of the cervix
Hysterectomy.
Patients must be able to avoid direct contact with pregnant or nursing women, infants and immunocompromised individuals during the days of reolysin treatment and for two days after
Unable to avoid close contact or household contact with the following high-risk individuals for three weeks after the day 1 vaccination: (a) children =< 3 years of age, (b) pregnant or nursing women, (c) individuals with prior or concurrent extensive eczema or other eczemoid skin disorders, or (d) immunocompromised individuals, such as those with HIV
Unable to avoid close contact or household contact with the following high-risk individuals for three weeks after the day 1 vaccination: (a) children =< 3 years of age, (b) pregnant or nursing women, (c) individuals with prior or concurrent extensive eczema or other eczemoid skin disorders, or (d) immunocompromised individuals, such as those with HIV
Patients unable to avoid close contact or household contact with the following high-risk individuals for three weeks after the day 1 vaccination: (a) children =< 3 years of age, (b) pregnant or nursing women, (c) individuals with prior or concurrent extensive eczema or other eczematoid skin disorders, or (d) immunocompromised individuals, such as those with human immunodeficiency virus (HIV)
Unable to avoid close contact or household contact with the following high-risk individuals for three weeks after the day 1 vaccination: (a) children =< 3 years of age, (b) pregnant or nursing women, (c) individuals with prior or concurrent extensive eczema or other eczemoid skin disorders, or (d) immunocompromised individuals, such as those with HIV
Must be able to avoid direct contact with pregnant women, infants < 3 months of age and immunocompromised individuals while on study and for >= 3 weeks following the last dose of study agent administration; direct contact is defined as household contact, i.e., anyone living with the patient
Unable to avoid close contact or household contact with the following high-risk individuals for three weeks after the day 1 vaccination: (a) children =< 3 years of age, (b) pregnant or nursing women, (c) individuals with prior or concurrent extensive eczema or other eczemoid skin disorders, or (d) immunocompromised individuals, such as those with HIV
Unable to avoid close contact or household contact with the following high-risk individuals for three weeks after the day 1 vaccination: (a) children =< 3 years of age, (b) pregnant or nursing women, (c) individuals with prior or concurrent extensive eczema or other eczemoid skin disorders, or (d) immunocompromised individuals, such as those with human immunodeficiency virus (HIV)
Inability to avoid close contact or household contact with the following high-risk individuals for three weeks after the day 1 vaccination or until the vaccination site heals completely: (a) children =< 3 years of age, (b) pregnant or nursing women, (c) individuals with prior or concurrent extensive eczema or other eczemoid skin disorders, or (d) immunocompromised individuals, such as those with HIV
Unable to avoid close contact or household contact with the following high-risk individuals for three weeks after the day 1 vaccination or until the vaccination site heals completely: (a) children =< 3 years of age, (b) pregnant or nursing women, (c) individuals with prior or concurrent extensive eczema or other eczemoid skin disorders, (d) individuals with other acute, chronic, or exfoliative skin condition, or (e) immunocompromised or immunosuppressed persons (by disease or therapy)